

FOI Ref: 26/188

10th April 2026

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

1. Does your Trust treat patients for head and neck cancer (Squamous cell carcinoma)? If no, which Trust do you refer patients onto for treatment?

No, East Sussex Healthcare NHS Trust (ESHT) does not treat patients for head and neck cancer. Patients are referred to University Hospitals Sussex NHS Foundation Trust (UHSussex). Please refer your request direct to UHSussex for a response to your FOI request, via the following email address:

uhsussex.foi@nhs.net

2. Within your trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following?

- **Surgery only**
- **Radiotherapy only**
- **Surgery + Radiotherapy**
- **Carboplatin (only or in combination with 5-FU)**
- **Cisplatin (only or in combination with 5-FU)**
- **Cetuximab with/without chemotherapy**
- **Cetuximab with radiotherapy**
- **Pembrolizumab monotherapy**
- **Pembrolizumab with chemotherapy**
- **Nivolumab**
- **Docetaxel (only or in combination with 5-FU)**
- **Fluorouracil (5FU) monotherapy**
- **Any other chemotherapy (without radiotherapy)**
- **Any other chemotherapy (with radiotherapy)**

Not applicable.

3. Could you please provide the number of patients treated in the past 3 months with the following agents for metastatic head and neck cancer (squamous cell carcinoma)?

- **Cetuximab with/without chemotherapy**
- **Pembrolizumab monotherapy**
- **Pembrolizumab with chemotherapy**
- **Nivolumab**
- **Docetaxel (only or in combination with 5-FU)**
- **Any other chemotherapy (without radiotherapy)**
- **Any other chemotherapy (with radiotherapy)**

Not applicable.

4. How many patients who received Pembrolizumab for head and neck cancer (squamous cell carcinoma) in the last 3 months, received:

- **Treatment every 3 weeks (200mg, Q3W)**
- **Treatment every 6 weeks (400mg, Q6W)**

Not applicable.

5. Does your trust participate in any clinical trials for head and neck cancer? If so, please provide the trial details and number of patients who are taking part.

No, ESHT does not participate in any clinical trials for head and neck cancer as they are treated at UHSussex.

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
East Sussex Healthcare NHS Trust
0300 131 4716
Core Hours of Business: Monday to Friday 9.00am to 4.00pm